Clinical trials: Diseases of Aortic Valve
Cognitive Decline, Stroke
Identification of Epigenetic Risk Factors for Ischemic Complication During the TAVR Procedure in the Elderly
Over the past ten years, the number of endovascular procedures has increased by 5% per year in Europe with the development of interventional cardiology, such as percutaneous coronary angioplasty, aortic valve replacements (TAVR)…
- Trial name
- METHYSTROKE (NCT02972008)
- Where
- France
- Volunteers
- 542 people
- Sponsor
- University Hospital, Lille
Aortic Valve Stenosis, Aortic Valve Stenosis With Insufficiency
Surgical Treatment of Aortic Stenosis With a Next Generation, Rapid Deployment Surgical Aortic Valve
The purpose of the clinical study is to prove that the heart valve device is safe, effective, and performs as intended.
- Conditions
- Aortic Valve Stenosis, Aortic Valve Stenosis With Insufficiency, Regurgitation, Aortic Valve, Aortic Valve Incompetence
- Trial name
- TRANSFORM™ (NCT01700439)
- Testing
- EDWARDS INTUITY valve
- Where
- 29 sites in United States
- Volunteers
- 934 people
- Sponsor
- Edwards Lifesciences
Aortic Stenosis, Valvular Heart Disease
SMART Watch Facilitated Early Discharge in Patients Undergoing Transcatheter Aortic Valve Replacement
The purpose of this study is to observe conduction disturbance, daily activity level, heart rates, oxygen saturation in patients who underwent Transcatheter Aortic Valve Replacement (TAVR) and to evaluate the utility of the…
- Conditions
- Aortic Stenosis, Valvular Heart Disease, Transcatheter Aortic Valve Replacement
- Trial name
- SMART TAVR (NCT04454177)
- Testing
- HUAWEI watch
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Breastfeeding, Hypertrophic Cardiomyopathy
Mavacamten Pregnancy Surveillance Program
The purpose of this observational pregnancy safety study is to assess maternal, fetal, and infant outcomes after exposure to mavacamten at any time during pregnancy and/or breastfeeding.
- Conditions
- Breastfeeding, Hypertrophic Cardiomyopathy, Pregnancy Related
- Trial name
- NCT05939700
- Testing
- Mavacamten
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Bristol-Myers Squibb
Coronary Artery Disease, Aortic Valve Disease
Deploying Novel Imaging Modalities Towards a Three-dimensional (3D) CARDIOvascular PATHology
The goal of the 3D-CARDIOPATH study is to investigate the potential added value of emerging 3D imaging modalities by imaging ex vivo cardiac specimens (diseased coronary arteries, calcific aortic valves, and thrombotic materials)…
- Conditions
- Coronary Artery Disease, Aortic Valve Disease, Aortic Valve Calcification, STEMI
- Trial name
- 3D-CARDIOPATH (NCT05975567)
- Testing
- Three-dimensional imaging of the collected cardiac specimens
- Volunteers
- 70 people
- Sponsor
- Aristotle University Of Thessaloniki
Aortic Valve Regurgitation
Transcatheter Aortic Valve Replacement for Pure Severe Aortic Valve Regurgitation
The purpose of this multicenter, prospective and observational registry is to evaluate the safety and efficacy of TAVR for treatment of pure severe aortic valve regurgitation.
- Trial name
- NCT06381271
- Testing
- Transcatheter aortic valve replacement
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Xijing Hospital
Hypertrophic Obstructive Cardiomyopathy \(HOCM\)
Myocardial Perfusion Changes Following Optimal Medical Treatment in Symptomatic Hypertrophic Cardiomyopathy
Background: Microvascular dysfunction is a hallmark of hypertrophic obstructive cardiomyopathy (HOCM) and can be visualized non-invasively using cardiac magnetic resonance (CMR) perfusion imaging.
- Trial name
- oHCM (NCT07150299)
- Testing
- Mavacamten in clinical routine use
- Where
- Austria
- Volunteers
- 20 people
- Sponsor
- Medical University of Vienna
Transcatheter Aortic Valve Implantation
Investigation of the NVT ALLEGRA Plus THV System in Patients With Severe Aortic Stenosis or Failed Surgical Aortic Bioprosthesis
The EMPIRE II study evaluates the safety and performance of the entire ALLEGRA THV System. The primary safety endpoint is composite of all-cause mortality or stroke rates at 12 months.
- Trial name
- EMPIRE-II (NCT05804903)
- Testing
- (ALLEGRA Plus Transcatheter Heart Valve) TAVI in severe calcified aortic stenosis or in failed surgical aortic bioprosthesis
- Where
- 7 sites in Finland, Germany and 3 more
- Volunteers
- 177 people
- Sponsor
- NVT GmbH
Aortic Stenosis, Ascending Aortic Dilatation
Comparison of Self- and Balloon-expandable Valves in Patients With Ascending Aortic Dilation Undergoing Transcatheter Aortic Valve Replacement: The AAD-CHOICE
This study aimed at comparing the performance of self-expandable valves versus balloon-expandable valves in patients with ascending aortic dilation undergoing transcatheter aortic valve replacement.
- Trial name
- NCT06009588
- Testing
- self-expandable valves, balloon-expandable valves
- Where
- China
- Volunteers
- 100 people
- Sponsor
- China National Center for Cardiovascular Diseases
Aortic Valve Stenosis
Engager Align Post-market Clinical Study
Purpose To characterize the safety and clinical benefit of the Engager Transcatheter Aortic Valve Implantation System in a real world environment.
- Trial name
- NCT02149654
- Testing
- Engager Transcatheter Aortic Valve Implantation System
- Where
- Netherlands
- Volunteers
- 27 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Coronary Artery Disease, Aortic Valve Stenosis
Comparative Analysis of the Microcirculation During Cardiac Surgery With Minimal Invasive Versus Conventional Extracorporeal Circulation
The aim of the proposed study is to evaluate microcirculatory alterations in patients undergoing open heart surgery with minimal invasive versus conventional extracorporeal circulation.
- Conditions
- Coronary Artery Disease, Aortic Valve Stenosis, Mitral Disease
- Trial name
- NCT05479188
- Testing
- Sublingual microscopy
- Where
- Greece
- Volunteers
- 60 people
- Sponsor
- Aristotle University Of Thessaloniki
Velocardiofacial Syndrome, Williams Syndrome
The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome
The purpose of this study is to investigate the Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome (VCFS), Williams Syndrome (WS)and Fragile X Syndrome Characterization, Treatment and Examining the Connection to…
- Conditions
- Velocardiofacial Syndrome, Williams Syndrome, Fragile X Syndrome
- Trial name
- VCFS (NCT00768820)
- Testing
- methylphenidate, fluoxetin, risperidone
- Where
- Israel
- Volunteers
- 400 people
- Sponsor
- The Chaim Sheba Medical Center
Aortic Valve Stenosis
Preoperative CT-imaging with Patient-specific Computer Simulation in Transcatheter Aortic Valve Replacement
Combining routine preoperative CT imaging with patient-specific computer modelling predicts the interaction between different sizes of transcatheter aortic valve replacement devices at different implantation depths and the…
- Trial name
- GUIDE-TAVI (NCT05788770)
- Testing
- FEops HEARTGuide
- Where
- 2 sites in Austria, Netherlands
- Volunteers
- 454 people
- Sponsor
- Romy Hegeman
Aortic Valve Disease
Left Bundle Branch Block (LBBB) After IntuityTM
This study aimed to evaluate incidence, prognosis and predictive factors of new-onset of persistent left bundle branch block (LBBB) after rapid-deployment aortic valve replacement (RD-AVR) with the IntuityTM bioprosthesis.
- Trial name
- NCT04897659
- Where
- France
- Volunteers
- 274 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Patients Above 18 Years, Patient Discharge
One Year Pacing Dependency After TAVR
Pace maker implantation after the procedure of TAVR can be estimated at 15% of patients. However, some studies have shown that the conduction disturbances after TAVR could resolve over time, and that roughly between one- and…
- Conditions
- Patients Above 18 Years, Patient Discharge, Pacing Therapy, Aortic Stenosis (Treated With TAVI)
- Trial name
- PACETAVI (NCT06756282)
- Testing
- Pacemaker and defibrillator
- Where
- France
- Volunteers
- 90 people
- Sponsor
- University Hospital, Montpellier
Aortic Valve Stenosis
Impact of Beta Blockers on TAVI (BETA-TAVI)
The BETA-TAVI trial is a prospective, investigator-initiated, multicenter, randomized, open-label, non-inferiority trial designed to evaluate the safety of continuing versus temporarily interrupting chronic beta-blocker therapy…
- Trial name
- BETA-TAVI (NCT05721170)
- Testing
- Beta blocker
- Where
- 2 sites in Cyprus, Greece
- Volunteers
- 348 people
- Sponsor
- National and Kapodistrian University of Athens
Williams-Beuren Syndrome, Micro-duplication 7q11.23 Syndrome
Quantification of Elastin Markers Synthesis in Williams-Beuren Syndrome and 7q11.23 Micro-duplication Syndrome
Introduction: Williams-Beuren syndrome is a rare genetic disorder caused by a 7q11.23 microdeletion. The phenotype associates vasculopathy (arterial stenosis, hypertension), dimorphism and intellectual disability.
- Conditions
- Williams-Beuren Syndrome, Micro-duplication 7q11.23 Syndrome, Vasculopathy
- Trial name
- ELAST7 (NCT04051086)
- Testing
- Physical examination and Urine and blood samples, Urine and blood samples
- Where
- France
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Aortic Stenosis, Aortic Valve Stenosis
Angiotensin Receptor Blockers in Aortic Stenosis
This study is intended to investigate the effect of angiotensin receptor blockers (ARBs) on mild-to-moderate aortic stenosis.
- Trial name
- ARBAS (NCT04913870)
- Testing
- Angiotensin Receptor Blockers
- Where
- 2 sites in Canada, Denmark
- Volunteers
- 144 people
- Sponsor
- Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
Severe Native Aortic Stenosis
International Multicenter Study of the Navitor/Navitor Vision Transcatheter Aortic Valve Platform
INTENSIVE is a prospective, single-arm, multi-center, international, investigator-initiated study of the Navitor/Navitor Vision Transcatheter Aortic Valve (Navitor/Navitor Vision Valve) in patients with symptomatic, severe native…
- Trial name
- Intensive (NCT07359898)
- Where
- Italy
- Volunteers
- 1,000 people
- Sponsor
- IRCCS Policlinico S. Donato
Aortic Valve Insufficiency, Regurgitation, Aortic Valve
Aortic Valve Replacement With Trifecta(TM)
To confirm the clinical safety and effectiveness of the Trifecta valve.
- Conditions
- Aortic Valve Insufficiency, Regurgitation, Aortic Valve, Aortic Valve Incompetence, Aortic Valve Stenosis
- Trial name
- NCT00475709
- Testing
- Trifecta Aortic Heart Valve
- Where
- 18 sites in United States
- Volunteers
- 1,022 people
- Sponsor
- Abbott Medical Devices
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.